"Apixaban's Efficacy in Preventing Stroke Recurrence in Atrial Cardiopathy Patients"

A randomized clinical trial of 1015 patients with cryptogenic stroke and evidence of atrial cardiopathy found that the rate of recurrent stroke did not significantly differ between the apixaban group and the aspirin group. The trial was stopped for futility after a planned interim analysis, concluding that in patients with cryptogenic stroke and evidence of atrial cardiopathy without atrial fibrillation, apixaban did not significantly reduce recurrent stroke risk compared with aspirin. Atrial cardiopathy, associated with stroke in the absence of clinically apparent atrial fibrillation, remains a challenge for stroke prevention.